| Document |
Document Title |
|
WO/2015/108038A1 |
The present invention addresses the problem of providing: a compound which is useful for the prevention or treatment of hyperphosphatemia or a hyperphosphatemia-related disease, or a pharmacologically acceptable salt of the compound; and...
|
|
WO/2015/106674A1 |
The present invention relates to a crystal form 1 of anacetrapib. Compared with the prior art, the crystal form 1 of anacetrapib of the present invention has a better crystal form stability, is easily stored, and is suitable for use as a...
|
|
WO/2015/108136A1 |
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...
|
|
WO/2015/107541A1 |
The present invention relates to compounds of the general formula (I), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods for their preparation, use ...
|
|
WO/2015/103526A1 |
Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-t...
|
|
WO/2015/102369A1 |
The present invention relates to a compound represented by chemical formula (1), a pharmaceutically acceptable salt thereof, a hydrate, a solvate, a prodrug, a tautomer, an enantiomer, or a pharmaceutically acceptable diastereomer, a met...
|
|
WO/2015/091647A1 |
A compound of formula (I) or a salt thereof are provided wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions ass...
|
|
WO/2015/083560A1 |
The present invention addresses the problem of providing a novel bis(hydroxyphenyl)benzoxazole compound which is useful as a raw material resin for resins such as epoxy and polybenzoxazole, and as a medicine, agrochemical, dye and electr...
|
|
WO/2015/071165A1 |
The present invention discloses novel compounds and their use in medicine. Preferably the compounds are applicable in the therapy of disorders associated with damaged post-mitotic tissues in mammals. The novel compounds are compounds acc...
|
|
WO/2015/068121A1 |
The present invention relates to a process for the preparation of crystalline form I of linezolid, comprising providing a solution of linezolid in a solvent, crystallizing and recovering the solid of Linezolid in crystalline form I at el...
|
|
WO/2015/068171A1 |
A novel oxazolidinone compound (S)-N-((3-(4-fluoro-3-morpholinophenyl)-2-oxooxazolidin-5-yl
)methyl)acetamide of formula -I and a process for the preparation thereof. Compound-I.
|
|
WO/2015/069110A1 |
The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic...
|
|
WO/2015/064532A1 |
The purpose of the present invention is to prevent or treat hyperphosphatemia or disease associated with hyperphosphatemia. To fulfill this purpose, a compound having general formula (I), or a pharmaceutically acceptable salt thereof, is...
|
|
WO/2015/066413A1 |
This invention pertains generally to treating bacterial infections using organic compounds of Formula I. In certain aspects, the invention pertains to treating infections caused by Gram-negative bacteria. (I) wherein X, Y, R1, R2, R3, R4...
|
|
WO/2015/061518A1 |
Compounds of Formula I with activity against HIV, including pharmaceutical compositions and methods for using these compounds in treating human immunodeficiency virus (HIV) infection, are set forth: Formula :(I)
|
|
WO/2015/055994A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, L, X, Ra, Rb, R1, R2 and R3 their preparation, pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2015/054103A1 |
The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be us...
|
|
WO/2015/054038A1 |
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
WO/2015/054089A1 |
This invention relates to a compounds of formula (I) which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bo...
|
|
WO/2015/044163A1 |
The invention relates to substituted phenylalanine derivatives and to methods for the production thereof, in addition to the use of said derivatives for producing drugs for the treatment and/or prophylaxis of diseases, in particular card...
|
|
WO/2015/039172A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2015/039592A1 |
The present invention relates to the compound of formula (I), derivatives thereof, compositions comprising same, and the use thereof in the preparation of pharmaceuticals for the treatment and prevention of diseases benefitting from the ...
|
|
WO/2015/032423A1 |
The invention provides a compound which is an amide of the formula (2): or a salt or stereoisomer thereof; wherein: R7 is selected from chlorine and fluorine; R3, R4, R5 and R6 are each independently selected from hydrogen, fluorine and ...
|
|
WO/2015/027772A1 |
Disclosed are phenanthrene-containing heterocyclic compounds shown as general formula (I) and preparation method therefor and application thereof on pesticides. The synthetic method of the compounds is simple and easy to industrialize. T...
|
|
WO/2015/030106A1 |
The present invention relates to compounds represented by general formula (I) (where Z, R, Ra, R', * and n are each as defined in the description) or salts thereof.
|
|
WO/2015/027146A1 |
A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for th...
|
|
WO/2015/022228A1 |
Use of a radiation curable composition as printing ink for ink-jet printing, wherein the radiation curable composition comprises N-vinyloxazolidinone of formula (I) in which R1 to R4 independently from each other are a hydrogen atom or a...
|
|
WO/2015/010297A1 |
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
|
|
WO/2015/010626A1 |
Provided are therapeutically active compounds and the use in manufacture of medicaments for treating a cancer characterized by the presence of a mutant allele of IDH1.
|
|
WO/2015/006100A1 |
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
|
|
WO/2015/004306A1 |
The present invention relates to a family of differently substituted oxazolidinones and to the pharmaceutically acceptable salts, esters, prodrugs, tautomers, solvates and hydrates thereof, which show an affinity for the alpha and gamma ...
|
|
WO/2015/002230A1 |
The present invention relates to compounds (I), which have RORγt inhibitory effects, and salts thereof. In formula (I), each notation is as described in the Specification. (I)
|
|
WO/2014/208767A1 |
A colored curable resin composition which comprises a colorant, a resin, a polymerizable compound, a polymerization initiator and a solvent, wherein the colorant includes a compound represented by formula (I). (In the formula, L is a sul...
|
|
WO/2014/207001A1 |
The present invention relates to a novel method for producing 2- phenyl-1,3-benzoxazoles of formula (I).
|
|
WO/2014/203217A1 |
The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modul...
|
|
WO/2014/199164A1 |
The invention relates to heterocyclic derivatives, to the use of said derivatives in treating a range of metabolic diseases and other conditions mediated by agonism of the G-protein coupled bile acid GPBAR1/TGR5 receptor, to compositions...
|
|
WO/2014/195231A1 |
The invention relates to substituted benzoxazoles of formula (1) where R1 represents a group of formula (II), (III), (IV), (V), and to a method for preparing same and their use in the production of drugs for the treatment and/or preventi...
|
|
WO/2014/188377A2 |
The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful rea...
|
|
WO/2014/186571A1 |
Bezoxazole sulfenamide accelerators are provided. The bezoxazole sulfenamide accelerators may be used in cure system for the vulcanization of rubber. The bezoxazole sulfenamide accelerators may also be used in asphalt and polymer composi...
|
|
WO/2014/181788A1 |
The present invention provides: a novel α-substituted glycineamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the α-substituted glycineamide derivative or a pharmacologically acce...
|
|
WO/2014/181287A1 |
The present invention provides heterocyclyl compounds of formula I, isotopic forms, stereoisomers or tautomers thereof, or pharmaceutically acceptable salts, solvates, N- oxides, S-oxides and polymorphs thereof, and processes for their p...
|
|
WO/2014/178381A1 |
Provided is a new compound having glycogen synthase activation potency, but minimal activation of receptor PPAR, and a high degree of safety. A compound represented by general formula [I], or a pharmaceutically acceptable salt thereof....
|
|
WO/2014/174745A1 |
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...
|
|
WO/2014/175832A1 |
The invention provides a compound of structure Ar1-Ar2-X-C(R1R2)-C(=O)-N(R3)-Ar3-Ar4 for modulating WNT activity. In this structure, Ar1, Ar2, Ar3 and Ar4 are, independently, optionally substituted aryl or heteroaryl groups; R1 and R3 ar...
|
|
WO/2014/164667A1 |
Compounds and methods of treating or preventing a Flavivirus infection in a subject are provided. The methods comprise administering to the subject a therapeutically effective amount of a compound as described herein. The methods are use...
|
|
WO/2014/163162A1 |
The present invention pertains to a compound indicated by formula (I), said compound being useful as a prophylactic or treatment agent for epilepsy and neurodegenerative diseases, etc. In the formula (I), each symbol is as defined in the...
|
|
WO/2014/157607A1 |
Provided is a method for improving the optical purity of optically active 2-hydroxycarboxylic acids that are useful as raw materials in the manufacture of drugs, agricultural chemicals, and industrial products. A method for improving the...
|
|
WO/2014/154726A1 |
The present invention relates to compounds of the formula (I), wherein X, R, R1, R2, D, E1, E2, E3, E4, G1, G2, G3 and G4 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. They are inhibitors ...
|
|
WO/2014/157296A1 |
Provided is a photosensitive resin composition which provides a pixel (a cured film of the photosensitive resin composition) having high transparency and high refractive index, while generating less development residue during the pixel f...
|
|
WO/2014/155264A1 |
The present invention provides an improved and commercial process for the preparation of Lacosamide having formula (I). Further, the present invention also provides the novel intermediate compounds of formula (VI) and (VII) and their pro...
|
